Literature DB >> 25583797

Addressing the controversy: do bisphosphonates directly affect primary tumors?

Julie A Sterling1.   

Abstract

The recent article by Junankar and colleagues focuses on demonstrating the uptake of bisphosphonates (BP) into the primary tumor in both animal models and human samples. Interestingly, the authors were able to establish tumor-associated macrophages as the cell type that takes up the BPs. These studies are an important advancement for understanding the potential benefits of using BPs as adjuvant therapy in patients with cancer. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25583797      PMCID: PMC4295645          DOI: 10.1158/2159-8290.CD-14-1380

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  8 in total

Review 1.  Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages.

Authors:  A J Roelofs; K Thompson; F H Ebetino; M J Rogers; F P Coxon
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

2.  Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer.

Authors:  Simon Junankar; Gemma Shay; Julie Jurczyluk; Naveid Ali; Jenny Down; Nicholas Pocock; Andrew Parker; Akira Nguyen; Shuting Sun; Boris Kashemirov; Charles E McKenna; Peter I Croucher; Alexander Swarbrick; Katherine Weilbaecher; Tri Giang Phan; Michael J Rogers
Journal:  Cancer Discov       Date:  2014-10-13       Impact factor: 39.397

Review 3.  Molecular mechanisms of action of bisphosphonates: current status.

Authors:  Anke J Roelofs; Keith Thompson; Sharon Gordon; Michael J Rogers
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

Review 4.  Bisphosphonates: the first 40 years.

Authors:  R Graham G Russell
Journal:  Bone       Date:  2011-05-01       Impact factor: 4.398

5.  Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.

Authors:  Robert Coleman; David Cameron; David Dodwell; Richard Bell; Caroline Wilson; Emma Rathbone; Maccon Keane; Miguel Gil; Roger Burkinshaw; Robert Grieve; Peter Barrett-Lee; Diana Ritchie; Victoria Liversedge; Samantha Hinsley; Helen Marshall
Journal:  Lancet Oncol       Date:  2014-07-15       Impact factor: 41.316

6.  Breast-cancer adjuvant therapy with zoledronic acid.

Authors:  Robert E Coleman; Helen Marshall; David Cameron; David Dodwell; Roger Burkinshaw; Maccon Keane; Miguel Gil; Stephen J Houston; Robert J Grieve; Peter J Barrett-Lee; Diana Ritchie; Julia Pugh; Claire Gaunt; Una Rea; Jennifer Peterson; Claire Davies; Victoria Hiley; Walter Gregory; Richard Bell
Journal:  N Engl J Med       Date:  2011-09-25       Impact factor: 91.245

Review 7.  Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.

Authors:  Ingunn Holen; Robert E Coleman
Journal:  Breast Cancer Res       Date:  2010-12-16       Impact factor: 6.466

Review 8.  Tumour macrophages as potential targets of bisphosphonates.

Authors:  Thea L Rogers; Ingunn Holen
Journal:  J Transl Med       Date:  2011-10-17       Impact factor: 5.531

  8 in total
  1 in total

Review 1.  Cellular and Molecular Mediators of Bone Metastatic Lesions.

Authors:  Giulia Battafarano; Michela Rossi; Francesco Marampon; Andrea Del Fattore
Journal:  Int J Mol Sci       Date:  2018-06-08       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.